| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 1b data readout example | AGMB-447 Idiopathic Pulmonary Fibrosis (IPF) | Phase 1b | — | Small Molecules | Respiratory System | ||
Phase 1b data readout example | AGMB-447 Idiopathic Pulmonary Fibrosis (IPF) | Phase 1b | — | Small Molecules | Respiratory System | ||
Phase 1b data readout example | AGMB-447 Idiopathic Pulmonary Fibrosis (IPF) | Phase 1b | — | Small Molecules | Respiratory System |
Recent Updates
Recently added Catalysts
AgomAb Therapeutics NV$10.98
+0.88 (+8.71%)
D 29Pipeline Score Overvalued Biotech · Clinical
Market Cap
560.47 M
EPS
-
P/E Ratio
-
Value Trade
1.08 M
4.26 %
Week
4.03 %
1 Month
-25.81 %
3 Month
-20.96 %
6 Month
-20.96 %
5 Year
-20.96 %
All Time
Cash Data
Cash Position
12.35 K
Monthly Burn
12.35 K
Runway
12,345 mo
Overview
Volume
188.96 K
52 Week Range
9 - 17.45
% held by Insiders
25.59 %
% held by Institutions
22.06 %
Enterprise Value
425.11 M
Total Shares
48.74 M
Short %
2.18 %
Float Shares
36.13 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
D29
Pipeline Score $166M
Pipeline ValueOvervalued
Valuation Signal3
Drugs Scored0.3x
rNPV / MCap Top 33%
Micro Cap (rank 607 of 905)
Percentile RankAgomAb Therapeutics NV faces pipeline headwinds (29/100), with $637M risk-adjusted pipeline value, led by AGMB-129 in Fibrostenotic Crohn's Disease (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AGMB-129 Small molecule | Fibrostenotic Crohn's Disease | Phase 2 | NCT05843578 | 17% | $456M | ACTIVE NOT_RECRUITING | 133 | AVERAGE | B (69) | Sep 1, 2026 | - | LOW Jun 7, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in AGMB
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
AgomAb Therapeutics NV (AGMB) Analyst Ratings & Price Targets
Symbol
Firm
Rating
Action
Price Target
Upside
date
AGMB
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
AGMB
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
AGMB
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
AGMB Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
AGMB Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
AGMBAgomab Announces Results of Annual General Meeting
Agomab Therapeutics NV announced the successful outcomes of its Annual General Meeting held on May 26, 2026. All agenda items, including the approval of financial statements and reappointments of board members, were approved. The company continues to focus on developing therapies for fibro-inflammatory diseases.
Read more →AGMBAgomab Receives U.S. Patent for AGMB-447, its Inhaled Lung-restricted Small Molecule Inhibitor of ALK5 in Development for the Treatment of Idiopathic Pulmonary Fibrosis
Agomab Therapeutics has been granted a U.S. patent for AGMB-447, an inhaled small molecule inhibitor aimed at treating Idiopathic Pulmonary Fibrosis (IPF). This patent secures intellectual property rights for AGMB-447 until at least 2041. The drug is currently undergoing a Phase 1b study, with results expected later this year. Agomab emphasizes the potential of AGMB-447 to meet significant medical needs in IPF.
Read more →AGMBAgomab Announces Closing of Initial Public Offering
Agomab Therapeutics NV has successfully closed its initial public offering, raising approximately $200 million by offering 12.5 million American Depositary Shares at $16.00 each. The shares began trading on the Nasdaq Global Select Market under the ticker AGMB on February 6, 2026. The company is focused on developing therapies for chronic fibrotic diseases, addressing significant unmet medical needs.
Read more →AGMBAgomab Announces Pricing of Initial Public Offering
Agomab Therapeutics NV has announced the pricing of its initial public offering, aiming to raise $200 million by offering 12.5 million American Depositary Shares at $16.00 each. The shares are set to begin trading on the Nasdaq Global Select Market on February 6, 2026. The offering is expected to close on February 9, 2026, pending customary conditions.
Read more →Competitive Position
How AGMB ranks across every disease it competes inCompetitive Position is a premium feature
See how AGMB ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial